Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-SGE-REIC-NS
- Development stage
- Unknown
- Lead developer
- Momotaro-Gene
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intratumoral
01
Overview
Ad-SGE-REIC-NS is an investigational gene therapy developed by Momotaro-Gene Inc. for the treatment of recurrent malignant glioma. It utilizes a non-replicating adenovirus vector to deliver the Reduced Expression in Immortalized Cells (REIC)/Dickkopf-3 (DKK3) gene, a tumor suppressor that is frequently downregulated in various malignancies. The SGE (Super Gene Expression) component refers to a specialized promoter system designed to significantly enhance the expression levels of the therapeutic gene within target cells. Upon delivery, the overexpression of REIC/DKK3 protein triggers endoplasmic reticulum (ER) stress-mediated apoptosis specifically in cancer cells while sparing normal cells. Furthermore, the therapy induces a bystander effect and stimulates systemic anti-tumor immunity by promoting the maturation of dendritic cells and the activation of cytotoxic T lymphocytes. Ad-SGE-REIC-NS is currently being evaluated in Phase I/II clinical trials, representing a second-generation advancement over the earlier MTG-201 (Ad-REIC) candidate.
- Other names
- Ad-SGE-REIC-NSAd-SGE-REIC
02
Targets
DKK3 (Dickkopf-related protein 3)
Beyond the preview
Go deeper on Ad-SGE-REIC-NS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-SGE-REIC-NS.